Tag Archives: What is Cdiff?

Dr. Michael Pride, a Pfizer Scientist, Leads a Team Searching For Ways to Improve Diagnosis, Prevention and Treatment of Clostridium difficile Infections

Dr. Pride of Pfizer leads a team that is searching for ways to improve diagnoses & treatment of C. difficile,

Dr. Michael Pride is the Executive Director, Vaccine Research and Development at Pfizer

Challenges, Chance and Looking Forward. Historically, a difficult diagnosis process has posed challenges to treatment for C. difficile infections, as detection is not straightforward. Dr. Pride and his team are working to tackle this issue by developing better ways to diagnose this infection, which will aid efforts to develop a vaccine. Additionally, he is encouraged by recent work that has demonstrated how an antibody can help prevent recurrent diseases, offering insight that an antibody-mediated response, raised by vaccines, may be a way to help reduce a primary episode of a C. difficile infection.

“If our vaccine is successful, we could help have a great impact on global health, reducing morbidity and even mortality worldwide,” he says. “I’m confident in our team, who is working tirelessly so that hopefully no one must suffer from these horrible symptoms again.”

Today, Dr. Pride leads a team of scientists responsible for the development, qualification and validation of various assays that support Pfizer’s vaccine programs.

 

 

Click on the link below to learn more about Dr. Michael Pride’s Work:

http://innovation.org/about-us/innovation-faces/researcher-profiles/michaelpride?utm_source=Twitter&utm_medium=Social&utm_campaign=NCAC&utm_term=02030501050201&utm_content=DrMichaelPride&sf200705754=1

 

C Diff Foundation ‘Making a Difference’ Award Presented to CutisPharma Inc.

The C Diff Foundation today announced that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

C Diff Foundation

C Diff Foundation’s ‘Making a Difference’ Award Presented at CutisPharma’s Pre-Launch Celebration for Newly Approved C.diff. Drug FIRVANQ

(NEW PORT RICHEY, Fla.) — NEWS: The C Diff Foundation announced today that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

The award was presented at CutisPharma’s celebration of its upcoming launch of FIRVANQ(TM), recently approved by the FDA for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Upon launch, FIRVANQ(TM) will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

“CutisPharma has been a committed partner of our Foundation and has furthered our mission to increase C.diff. awareness and support the research and development of new treatment options,” said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation. “In recognition of CutisPharma’s efforts, we are pleased to grant them the ‘Making a Difference’ award at this special moment in the Company’s 20th anniversary year.”

“We are very grateful to receive such a special distinction from the C Diff Foundation,” said Neal I. Muni, MD, MSPH, and Chief Executive Officer of CutisPharma. “For 20 years, we have been committed to improving the lives of patients who are not well-served by existing therapies and would benefit from high-quality, cost-effective new treatment options. We greatly value our partnership with the C Diff Foundation and look forward to continuing to support their mission.”

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3)non-profit organization, established in 2012, is comprised of 100 percent volunteering professionals dedicated to supporting public health initiatives for C. difficile infection prevention, treatments, environmental safety, and support worldwide. For more information, visit: https://cdifffoundation.org/.

About CutisPharma:

CutisPharma, Inc., based in Wilmington, Mass., is privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma’s FIRST(r) Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company’s first FDA-approved Kit, FIRVANQ(TM), will allow significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments. For more information, visit: https://cutispharma.com/.

 

Source:   https://enewschannels.com/c-diff-foundation-making-a-difference-award-presented-to-cutispharma-inc/

C. diff. Spores and More, Join Us and Celebrate

www.cdiffradio.com

C. diff. Spores and More

Sponsored by Clorox Healthcare

Join us and Celebrate

with our 81,453 listeners – so far –  in Season III.

We thank our listeners joining us every

Tuesday at 10:00 a.m. PT / 1:00 p.m. ET

across the U.S. A. and to our listeners in

  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Ireland
  • Israel
  • Japan
  • Malaysia
  • Peru
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Trinidad
  • Ukraine
  • UK    and Across the Globe

We also extend our sincere gratitude to the guests who take time out of their busy

schedules to join us on each live broadcast.  Though their words of wisdom and

by sharing the most up-to-date information with us raises awareness in so

many important areas of healthcare.

 

Season III concludes on October 31, 2017

and we will be gearing up for

the 5th Annual International C. diff. Awareness Conference & Health EXPO taking

place on November 9th and 10th at the University of Nevada – Las Vegas.

For conference information please click on the link below.

https://cdifffoundation.org/2017cdiffconference/about-nov-2017-annual-conference/

 

Join us in Season IV when we return on January 9th, 2018

as we continue bringing you updates that are focused on, but not limited to,

C. difficile infection prevention, treatments, clinical trials, environmental safety

and much more.

Thank you again for listening and we wish you and your families improved health,

continued healing, and the best day — which you all deserve!